Related Experiment Videos
ACTH 1-17 effects in oncology
La Ricerca in Clinica E in Laboratorio
|April 1, 1984
Summary
This study found that Synchrodyn-17 peptide treatment in cancer patients undergoing chemotherapy reduced nausea, vomiting, and weakness. However, it also led to side effects like skin pigmentation, sodium retention, and hypertension.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cytotoxic chemotherapy regimens (CMF, FAC, FAM) are associated with significant side effects.
- Nausea, vomiting, and weakness are common and distressing chemotherapy-induced side effects.
- The peptide Synchrodyn-17 is being investigated for its potential to mitigate these side effects.
Purpose of the Study:
- To evaluate the efficacy of Synchrodyn-17 in reducing chemotherapy-induced side effects.
- To assess the impact of Synchrodyn-17 on patient performance status.
- To identify any adverse effects associated with Synchrodyn-17 administration.
Main Methods:
- A study involving 90 cancer patients receiving cytotoxic chemotherapy.
- Treatment group received Synchrodyn-17 (100 micrograms i.m. daily for 15 days).
- Control group received a placebo.
Main Results:
- Synchrodyn-17 significantly reduced nausea, vomiting, and weakness compared to placebo.
- Patient performance status remained unchanged.
- Observed side effects included skin pigmentation, sodium retention, hypertension, and hyperglycemia.
Conclusions:
- Synchrodyn-17 demonstrates potential in alleviating key side effects of chemotherapy.
- Sustained high-dose peptide treatment may cause specific adverse effects.
- Further research is needed to understand the peptide's full impact and optimize its use.